ha14-1 has been researched along with B16 Melanoma in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niino, S | 1 |
| Nakamura, Y | 1 |
| Hirabayashi, Y | 1 |
| Nagano-Ito, M | 1 |
| Ichikawa, S | 1 |
1 other study available for ha14-1 and B16 Melanoma
| Article | Year |
|---|---|
A small molecule inhibitor of Bcl-2, HA14-1, also inhibits ceramide glucosyltransferase.
Topics: 4-Chloro-7-nitrobenzofurazan; Animals; Apoptosis; Benzopyrans; Cell Line; Ceramides; Drug Evaluation | 2013 |